ABN Amro Investment Solutions Sells 23,180 Shares of Merck & Co., Inc. $MRK

ABN Amro Investment Solutions cut its stake in Merck & Co., Inc. (NYSE:MRK) by 9.0% in the 1st quarter, HoldingsChannel.com reports. The firm owned 233,654 shares of the company’s stock after selling 23,180 shares during the quarter. ABN Amro Investment Solutions’ holdings in Merck & Co., Inc. were worth $28,106,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new stake in Merck & Co., Inc. during the fourth quarter worth $3,997,933,000. Wellington Management Group LLP boosted its holdings in Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $1,012,530,000. Jennison Associates LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $585,192,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Merck & Co., Inc. by 37.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after purchasing an additional 5,152,069 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Gilead announced that Phase 3 data from the investigational once-weekly oral HIV regimen combining islatravir and lenacapavir will be presented at AIDS 2026, with the primary endpoint showing maintained viral suppression in adults who switched therapies. The update highlights progress in a potentially important HIV program and could support long-term growth expectations. Article: Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
• Positive Sentiment: Phanes Therapeutics expanded its clinical trial collaboration with Merck to evaluate spevatamig with KEYTRUDA and chemotherapy in first-line biliary tract cancer. More combination-trial activity around KEYTRUDA reinforces Merck’s oncology franchise and keeps the company involved in additional mid- to long-term growth opportunities. Article: Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
• Neutral Sentiment: Analyst-focused coverage repeated the view that Wall Street’s bullish average rating suggests Merck is worth considering, but the article also questioned how reliable consensus broker recommendations are as a signal. This is more of a sentiment check than a new fundamental catalyst. Article: Is It Worth Investing in Merck (MRK) Based on Wall Street’s Bullish Views?
• Neutral Sentiment: Recent media commentary also noted that Merck had declined more than the broader market in the prior session and that one rating was lowered to Hold, but these items do not appear to reflect a major company-specific setback. Instead, they suggest some near-term caution after the recent move. Article: Merck (MRK) Declines More Than Market: Some Information for Investors
• Negative Sentiment: Coverage from Barron’s focused on what comes after Keytruda, underscoring investor concern about Merck’s long-term dependence on its flagship cancer drug and the need for a future standard-of-care franchise. That narrative can weigh on valuation if investors worry about the post-Keytruda pipeline. Article: What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on MRK shares. UBS Group raised their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. CICC Research initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective for the company. Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.94.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $126.27 on Wednesday. The company has a market capitalization of $311.86 billion, a P/E ratio of 35.57, a price-to-earnings-growth ratio of 4.95 and a beta of 0.19. The company’s 50-day moving average is $120.65 and its 200 day moving average is $117.29. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $131.74.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s payout ratio is 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.